<DOC>
	<DOCNO>NCT00821977</DOCNO>
	<brief_summary>This 2-3 period parallel group study adaptive element Type 2 diabetes patient receive vildagliptin monotherapy .</brief_summary>
	<brief_title>Efficacy Long-Term Safety Vildagliptin Monotherapy Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Patients least 18 year age Visit 1 Drug naïve patient T2DM diagnose least 2 month prior Visit 1 HbA1c ≥ 7.0 % ≤ 10.0 % Visit 1 Body Mass Index ( BMI ) range 2245 kg/m2 Visit 1 Pregnant lactate female FPG ≥ 270 mg/dL ( ≥15 mmol/L ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Vildagliptin</keyword>
</DOC>